Drugs based on GLP-1, such as Ozempic, Wegovy, Mounjaro, and Zepbound, have quickly become popular treatments for weight loss, transforming the way patients and doctors think about obesity and related conditions. These medications reduce appetite by acting on hormones that affect hunger, leading many users to eat less and shed pounds. Clinical studies have shown that the drugs can deliver rapid and robust weight loss, sometimes even for people whose weight was stable for years.
However, experts caution that these benefits also come with important risks and new challenges. One concern is that suppressing appetite may mean patients eat too little of necessary nutrients, increasing the chance of vitamin and mineral deficiencies. For example, if users do not consume enough vitamin C, they may risk developing deficiencies like scurvy, although this effect is indirect. Along with vitamin concerns, doctors have noted the possibility of losing muscle instead of just fat, especially when the medications are started or stopped suddenly. Regaining lost weight after discontinuing treatment, sometimes gaining back more than before, has also been observed. This pattern suggests that ongoing use may be needed to maintain results, but this raises questions for long-term care and overall health.
Researchers are now seeking ways to improve these outcomes. One group is studying how GLP-1 drugs interact with the body’s stress system, which produces hormones linked to muscle loss and overeating. They have developed an experimental antibody that blocks stress-related molecules, and in early studies with mice, it led to more fat loss and less muscle loss. Such work is also driving efforts to make the weight loss from GLP-1 drugs healthier and more sustainable over time. Human trials are expected to follow next.
Beyond weight loss, these drugs are showing promise for reducing the risks of heart attacks, strokes, and inflammation in people with heart disease. There are also new findings around sleep apnea, suggesting that medications like Zepbound may cut sleep apnea severity in people with obesity and heart conditions. Some researchers are now testing the drugs for possible benefits in treating addiction, as GLP-1 receptors are found in parts of the brain that control reward behavior. Early results in alcohol-use disorder are encouraging, and studies in other addictions are underway.
Doctors stress that GLP-1 drugs should not be used purely for cosmetic reasons or casual weight loss, and that risks can increase if they are misused by people without underlying health conditions. Most medical professionals prescribe them as part of a broader approach—including diet, exercise, and sometimes surgery—to help patients manage chronic metabolic diseases. As these drugs become more available and affordable, some worry about “yo-yo” effects and improper use. Patients like Christie Woodard, who credits GLP-1 therapy with helping her maintain a healthy weight and quality of life after other options failed, say continued awareness and care are essential. At the same time, ongoing research and open discussions are helping guide the safe and effective use of these powerful medicines.
